FOI release

Ocrevus (ocrelizumab)

Some or all of the information requested may not have been provided because we determined that the request was vexatious.

Case reference FOI2025/00741

Received 21 July 2025

Published 9 September 2025

Request

I’m writing this email to submit a Freedom of Information (FOI) request for “Ocrevus (ocrelizumab)”. Requesting document is listed below and please let me know if you need additional information. Requesting documents ‘Ocrevus (ocrelizumab)’ ▶ CSR for WA21092 (Phase 3) ▶ SAP for WA21493, NCT00676715 (Phase 2) (unblinded in November 2009, first CSR) ▶ CSR body for WA21493, NCT00676715 (Phase 2)

Response

See attached

Documents

• FOI2025_00741 (redacted).pdf (795.4 KB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.